Last reviewed · How we verify
NCT04747964
A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
Phase 1 trial testing STSP-0601 for Injection in Hemophilia in 16 participants. Completed in 19 April 2021.
19 April 2021
Quick facts
| Lead sponsor | Staidson (Beijing) Biopharmaceuticals Co., Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 16 |
| Start date | 15 January 2020 |
| Primary completion | 19 April 2021 |
| Estimated completion | 19 April 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- STSP-0601 for Injection — full drug profile →
- STSP-0601 for Injection — full drug profile →
- STSP-0601 for Injection — full drug profile →
- STSP-0601 for Injection — full drug profile →
- STSP-0601 for Injection — full drug profile →
- STSP-0601 for Injection — full drug profile →
Conditions studied
- Hemophilia — all drugs for Hemophilia →
Sponsor
Staidson (Beijing) Biopharmaceuticals Co., Ltd — full company profile →
Who can join
Adults 18 to 65, male only, with Hemophilia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will assess the pharmacokinetics and pharmacodynamics of STSP-0601 at six dose levels. The results will help identify the most optimal doses to treat bleedings in hemophilia patients with inhibitors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04747964
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of STSP-0601 for Injection
Trials testing the same drug.
- NCT06289166 — Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor · Phase 2 · completed
- NCT05619926 — Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor · Phase 2 · completed
- NCT05027230 — A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor · Phase 1, PHASE2 · completed
Other recruiting trials for Hemophilia
Currently open trials in the same condition.
- NCT07579585 — Effects of Photobiomodulation in Hemophilia Patients. · NA · recruiting
- NCT07406139 — PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） · Phase 4 · recruiting
- NCT07285460 — A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Year · Phase 3 · recruiting
- NCT07187661 — Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis · NA · recruiting
- NCT07099313 — Association of Prophylactic Treatment With Treatment Burden and Psychosocial Variables in Patients With Hemophilia · recruiting
Other Staidson (Beijing) Biopharmaceuticals Co., Ltd trials
Trials by the same sponsor.
- NCT07168161 — BDB-001 Phase III Trial in ANCA-Associated Vasculitis · Phase 3 · recruiting
- NCT06597422 — A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects · Phase 1 · completed
- NCT06563713 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STSP-0902 in Healthy Subjects · Phase 1 · completed
- NCT06289166 — Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor · Phase 2 · completed
- NCT06038916 — To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04747964 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Staidson (Beijing) Biopharmaceuticals Co., Ltd
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04747964.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing